Thermo Fisher expands plasmid manufacturing capabilities
Thermo Fisher Scientific announced it will build a new plasmid DNA manufacturing facility in Carlsbad, CA. Read More
Emedgene, Illumina partner on rare disease analysis
Emedgene and Illumina have partnered to interpret genomic data for rare diseases. Read More
Inovio to develop COVID-19 DNA-encoded monoclonal antibodies
Inovio, along with a team of scientists from the Wistar Institute, AstraZeneca, the University of Pennsylvania, and Indiana University, has received a $37.6 million grant from the Defense Advanced Research Projects Agency, a branch of the U.S. Department of Defense, to develop COVID-19 treatments. Read More
Lilly to acquire Prevail Therapeutics for $1B
Eli Lilly will acquire Prevail Therapeutics for a total consideration of up to $26.50 per share in cash, or an aggregate of approximately $1.04 billion, contingent on the first regulatory approval for commercial sale of a Prevail product in certain countries. Read More
AbbVie licenses anti-COVID-19 antibody for clinical development
Harbour BioMed and Utrecht University have licensed their fully human SARS-CoV-2 neutralizing antibody, 47D11, to AbbVie. AbbVie has initiated a phase I clinical trial of the antibody for the prevention and treatment of COVID-19, initially in the U.S. with the goal of expanding into Europe. Read More
Greenwich to develop multiantigen coronavirus vaccine
Greenwich LifeSciences has entered into an option agreement with Westport Bio to in-license a preclinical coronavirus vaccine program that is currently at the preclinical animal testing stage. Read More
GenScript supports InnoBation's development of CAR T therapies
GenScript Biotech has signed an agreement with InnoBation for cell line development and engineering and manufacturing services for InnoBation's good manufacturing practice plasmids and lentivirus products for chimeric antigen receptor (CAR) T-cell treatment products. Read More
AnGes acquires EmendoBio for $250M
Japan-based biopharmaceutical company AnGes has completed the acquisition of gene editing technology firm EmendoBio for $250 million. Read More
Allogene Overland to develop AlloCAR T therapies in Asia
Allogene Therapeutics and Overland Pharmaceuticals have formed Allogene Overland Biopharm, a joint venture focused on the development, manufacturing, and commercialization of allogeneic chimeric antigen receptor T-cell (AlloCAR T) therapies for patients in Asia. Read More
Eureka touts preclinical results for COVID-19 antibody nasal spray
Eureka Therapeutics has touted positive preclinical results for its InvisiMask antibody nasal spray. Read More
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
